News Lilly puts up to $2.75bn into Insilico alliance Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.
Market Access BIO-Europe Spring, Portugal: Propelling new wave innovation BIO-Europe Spring arrived in Lisbon, Portugal yesterday, running from 23rd to 25th March.
News MSD taps Quotient for IBD drug targets in $2.2bn deal MSD is paying $20m upfront to activate an alliance with Flagship's Quotient Therapeutics to find new targets in inflammatory bowel disease.
News Sanofi pays $180m for rights to Kali autoimmune drug Sanofi has licensed rights to Kali's trispecific T-cell engager KT501, in trials for rheumatoid arthritis, in a deal valued at nearly $1.2bn.
News Novo Nordisk beefs up in oral obesity drugs with Vivtex deal Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.
News Takeda signs $1.7bn AI alliance with Iambic Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
